Acumen Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $223.45 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Acumen Pharmaceuticals Inc had its IPO on 2021-07-01 under the ticker symbol ABOS.
The company operates in the Healthcare sector and Biotechnology industry. Acumen Pharmaceuticals Inc has a staff strength of 14 employees.
Shares of Acumen Pharmaceuticals Inc opened at $4.05 at the start of the last trading session i.e. 2023-03-25.
The stocks traded within a range of $3.83 - $4.05, and closed at $3.92.
This is a -1.51% slip from the previous day's closing price.
A total volume of 54,000 shares were traded at the close of the day’s session.
In the last one week, shares of Acumen Pharmaceuticals Inc have slipped by -2.24%.
Acumen Pharmaceuticals Inc's Key Ratios
Acumen Pharmaceuticals Inc has a market cap of $223.45 million, indicating a price to book ratio of 1.1987 and a price to sales ratio of 538.7842.
In the last 12-months Acumen Pharmaceuticals Inc’s revenue was $329000 with a gross profit of $-12305000 and an EBITDA of $-39381000. The EBITDA ratio measures Acumen Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Acumen Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -11.24% with a return of equity of -17.83%.
In Q3, Acumen Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Acumen Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $1.24 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Acumen Pharmaceuticals Inc’s profitability.
Acumen Pharmaceuticals Inc stock is trading at a EV to sales ratio of 89.674 and a EV to EBITDA ratio of -0.908. Its price to sales ratio in the trailing 12-months stood at 538.7842.
Acumen Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $203.26 million
- Total Liabilities
- $6.61 million
- Operating Cash Flow
- $55.92 million
- Capital Expenditure
- Dividend Payout Ratio
Acumen Pharmaceuticals Inc ended 2023 with $203.26 million in total assets and $0 in total liabilities. Its intangible assets were valued at $203.26 million while shareholder equity stood at $196.65 million.
Acumen Pharmaceuticals Inc ended 2023 with $337000.00 in deferred long-term liabilities, $6.61 million in other current liabilities, 4000.00 in common stock, $-157561000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $157.54 million and cash and short-term investments were $200.19 million. The company’s total short-term debt was $133,000 while long-term debt stood at $0.
Acumen Pharmaceuticals Inc’s total current assets stands at $202.56 million while long-term investments were $0.00 and short-term investments were $42.65 million. Its net receivables were $121000.00 compared to accounts payable of $2.08 million and inventory worth $201000.00.
In 2023, Acumen Pharmaceuticals Inc's operating cash flow was $55.92 million while its capital expenditure stood at $81000.
Comparatively, Acumen Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Acumen Pharmaceuticals Inc stock is currently trading at $3.92 per share. It touched a 52-week high of $10.97 and a 52-week low of $10.97. Analysts tracking the stock have a 12-month average target price of $15.83.
Its 50-day moving average was $5.3 and 200-day moving average was $5.78 The short ratio stood at 6.48 indicating a short percent outstanding of 0%.
Around 1556.8% of the company’s stock are held by insiders while 7431.8% are held by institutions.
Frequently Asked Questions About Acumen Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.